Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Crl
  6. /
  7. Azurity Pharmaceuticals, Inc.
CRL
•Azurity Pharmaceuticals, Inc.

Azurity Pharmaceuticals, Inc. – FDA CRL

Record Details

The FDA issued a Complete Response Letter (CRL) to Azurity Pharmaceuticals, Inc. for its New Drug Application (NDA 214273) concerning Zonisade (zonisamide) oral suspension. Submitted under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, the application cannot be approved in its present form due to several critical issues. Key concerns include manufacturing facility deficiencies. During a recent inspection, one facility received conveyed deficiencies requiring satisfactory resolution. Additionally, issues were identified with LM MANUFACTURING LIMITED through a record review, necessitating an on-site inspection for Current Good Manufacturing Practice (CGMP) compliance, which could not be conducted during the review cycle due to travel restrictions. Beyond manufacturing, the FDA requires revisions to carton and container labeling, including a specific Medication Guide statement per 21 CFR 208.24(d). A comprehensive safety update, detailed under 21 CFR 314.50(d)(5)(vi)(b), is also mandated, requiring detailed safety profile changes, combined data, and narrative summaries for adverse events. Azurity Pharmaceuticals must address all deficiencies and resubmit the application within one year. Approval is contingent on resolving these issues and successfully completing all required facility inspections.

Company
Azurity Pharmaceuticals, Inc.
Product type
Drugs
Office
Office of Neuroscience
Person
  • Bharathi Devarakonda, Ph.D., RAC
View Company Profile

ID · d2ef8944-f9dd-46b1-98c5-6e0480032749

Other documents for Azurity Pharmaceuticals, Inc.
  • WARNING_LETTER - 2023-03-02March 2, 2023
  • EIR - 2022-02-24February 24, 2022
  • EIR - 2019-07-26July 26, 2019
  • CRL
  • CRL

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Azurity Pharmaceuticals, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.